Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year. As part of the EU, access to the Greek pharmaceutical market is governed by EU directives concerning pharmaceutical regulations and registration. Regarding patent protection and intellectual property rights, the Greek policy follows a similar pattern to other member states and is monitored by the National Organisation of Medicines (EOF).

In Greece, there is universal coverage for pharmaceutical care. The main responsibility for planning and implementation of pharmaceutical policy lies with the Ministry of Health and Social Solidarity. Several other Ministries also share responsibilities for pharmaceutical issues. Pricing resides with the Ministry of development. The Ministry of Employment and Social Protection supervises social security organisations, and the Ministry of Economy & Financer is responsible for reimbursing medicinal products for civil servants.

In common with other EU nations, price controls and reimbursement policies are a source of much contention between government and the pharmaceutical industry. Recent changes to the pharmaceutical pricing policy has changed the pricing structure of many pharmaceuticals; the introduction of reference pricing has ensured that prices are slightly higher but the prices are still some of the lowest in the EU. Changes to the reimbursement structure has allowed the financially disadvantaged and those with specific conditions to carry on having fully reimbursed products, although reimbursement has now been scrapped for every product that is available without a prescription.